ArticleNature cancer2023
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer.
Open access · greenAbstract read
In one paragraph
Article in Nature cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 41 citations in OpenAlex.
- Cancers modulate processing and presentation of p53 neoantigens to evade T cell detection.Immunity · 2026Article
- Review
- Therapeutic vaccines for NSCLC: From mechanisms to clinical translation.Chinese medical journal pulmonary and critical care medicine · 2026Review
- cGAS-STING pathway activation drives the cold-to-hot tumor transition and sensitizes immunotherapy.Cancer biology & medicine · 2026Review
- Cancer Vaccine Strategies in Non-Small Cell Lung Cancer.Vaccines · 2026Review
- Heterologous prime-boost immunization of AAV-based neoantigen cancer vaccine induces anti-tumor immunity to inhibit tumor growth and relapse.Cancer immunology, immunotherapy : CII · 2026Article
- Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives.Journal of hematology & oncology · 2026Review
- Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives.Frontiers in immunology · 2026Review
- Molecular Mechanisms and Treatment Strategies of ALK-Positive Lung Cancer: A Beginner's Guide for Patients, Their Families and Carers.Thoracic cancer · 2025Review
- Prospects and Challenges of Lung Cancer Vaccines.Vaccines · 2025Review
- Anaplastic large cell lymphoma in children and adolescents.British journal of haematology · 2025Review
- Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines.Experimental hematology & oncology · 2025Review
- ALK in cancer: from function to therapeutic targeting.Nature reviews. Cancer · 2025Review
- Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood.Cancer immunology research · 2025Article
- Highlighting recent achievements to advance more effective cancer immunotherapy.Journal of experimental & clinical cancer research : CR · 2025Article
- Advances in the application of tumor vaccines and combination strategies: new perspectives in lung cancer treatment.Frontiers in immunology · 2025Review
- Characteristics of the immune microenvironment and their clinical significance in lung adenocarcinoma patients with different ALK fusion variants.Translational lung cancer research · 2024Article
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies.Biomedicines · 2024Article
- The 2024 Report on the Human Proteome from the HUPO Human Proteome Project.Journal of proteome research · 2024Review
- Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience.The journal of liquid biopsy · 2024Article
Corrections and comments
- Commented on by
Authors and funding
31 authors at 9 institutions in 4 countries.
Ines MotaDepartment of Pathology, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0003-1523-7134
Enrico PatruccoDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Cristina MastiniDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.ORCID 0000-0001-5380-2611
Navin R MahadevanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Tran C ThaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Elisa BergaggioDepartment of Pathology, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0002-9960-3674
Taek-Chin CheongDepartment of Pathology, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0002-0939-9412
Giulia LeonardiDepartment of Pathology, Boston Children's Hospital, Boston, MA, USA.
Elif Karaca-AtabayDepartment of Pathology, Boston Children's Hospital, Boston, MA, USA.
Marco CampisiDepartment of Pathology, Boston Children's Hospital, Boston, MA, USA.
Teresa PoggioDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Matteo MenottiDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.ORCID 0000-0002-1260-2389
Chiara AmbrogioDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.ORCID 0000-0003-4122-701X
Dario L LongoDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.ORCID 0000-0002-6906-9925
Susan KlaegerBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-0074-5163
Hasmik KeshishianBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Zsófia M SztupinszkiDanish Cancer Society Research Center, Copenhagen, Denmark.ORCID 0000-0002-8691-4086
Zoltan SzallasiDanish Cancer Society Research Center, Copenhagen, Denmark.ORCID 0000-0001-5395-7509
Derin B KeskinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-8496-6181
Jonathan S Duke-CohanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-9478-9609
Bruce ReinholdDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Steven A CarrBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-7203-4299
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-3348-5054
Kelly D MoynihanKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Darrell J IrvineKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-8637-1405
David A BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ellis L ReinherzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1048-5526
Claudia VoenaDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.ORCID 0000-0002-1324-1431
Mark M AwadDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rafael B BlascoDepartment of Pathology, Boston Children's Hospital, Boston, MA, USA. rafael.b.blasco@gmail.com.ORCID 0000-0001-8025-0306
Roberto ChiarleDepartment of Pathology, Boston Children's Hospital, Boston, MA, USA. roberto.chiarle@childrens.harvard.edu.ORCID 0000-0003-1564-8531
Boston Children's Hospital · USUniversity of Turin · ITBroad Institute · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USHoward Hughes Medical Institute · USInstitute of Biostructure and Bioimaging · ITMassachusetts Institute of Technology · USSemmelweis University · HU
Funding
Cancer Immune Monitoring and Analysis CenterU24CA224331 · NCI · DANA-FARBER CANCER INST · PI FRANK S HODI, Catherine Ju-Ying Wu · 2017 to 2026
$18.4MProject 3P50CA265826 · NCI · DANA-FARBER CANCER INST · PI David A Barbie · 2022 to 2026
$13.7MSystematic identification of minor histocompatibility antigens to address GVHDR01HL157174 · NHLBI · DANA-FARBER CANCER INST · PI HO, VINCENT TRIEN-VINH, KESKIN, DERIN B · 2022 to 2025
$3.0MLymph node-targeted molecular vaccinesR01EB022433 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI IRVINE, DARRELL J · 2016 to 2019
$1.4MNCI NIH HHS P50 CA265826NCI NIH HHS U24 CA224331NHLBI NIH HHS R01 HL157174NIBIB NIH HHS R01 EB022433
Abstract
Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is treated with ALK tyrosine kinase inhibitors (TKIs), but the lack of activity of immune checkpoint inhibitors (ICIs) is poorly understood. Here, we identified immunogenic ALK peptides to show that ICIs induced rejection of ALK
Indexed as
Cancer VaccinesCarcinoma, Non-Small-Cell LungLung NeoplasmsAnaplastic Lymphoma KinaseAnimalsCD8-Positive T-LymphocytesHumansMiceMice, TransgenicProtein Kinase InhibitorsProtein-Tyrosine KinasesReceptor Protein-Tyrosine KinasesVaccinationVaccines, SubunitAnaplastic Lymphoma KinaseCancer VaccinesProtein Kinase InhibitorsProtein-Tyrosine KinasesReceptor Protein-Tyrosine KinasesVaccines, Subunit
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.